Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATNXNASDAQ:CARANASDAQ:GTHXNASDAQ:NXTCNASDAQ:STOK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsCARACara Therapeutics$0.65-3.2%$0.83$0.50▼$4.67$35.54M0.7640,648 shs89,200 shsGTHXG1 Therapeutics$3.86-3.3%$3.69$1.08▼$5.00$201.61M1.731.29 million shs240,171 shsNXTCNextCure$1.37-4.9%$1.74$0.98▼$2.57$38.22M0.4232,032 shs52,635 shsSTOKStoke Therapeutics$11.32-2.9%$9.16$3.35▼$16.40$524.16M0.77972,289 shs162,377 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNXAthenex0.00%0.00%0.00%0.00%-82.49%CARACara Therapeutics-5.02%-8.24%-18.09%+18.95%-82.91%GTHXG1 Therapeutics-4.77%-6.78%-3.62%+3.91%+62.20%NXTCNextCure-5.88%-4.64%-27.64%+21.01%-5.26%STOKStoke Therapeutics+3.64%-0.51%+79.38%+140.91%+43.77%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNXAthenexN/AN/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics3.7366 of 5 stars3.41.00.04.21.81.71.3GTHXG1 Therapeutics3.5111 of 5 stars3.32.00.03.82.50.80.6NXTCNextCure3.9315 of 5 stars3.53.00.04.60.01.71.3STOKStoke Therapeutics4.0775 of 5 stars4.41.00.04.82.41.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNXAthenexN/AN/AN/AN/ACARACara Therapeutics2.75Moderate Buy$9.751,400.00% UpsideGTHXG1 Therapeutics2.50Moderate Buy$9.33141.80% UpsideNXTCNextCure3.00Buy$6.00337.96% UpsideSTOKStoke Therapeutics2.78Moderate Buy$19.6373.37% UpsideCurrent Analyst RatingsLatest CARA, STOK, ATNX, NXTC, and GTHX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.004/11/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/4/2024STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/26/2024STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $17.003/26/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $22.003/26/2024STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/26/2024STOKStoke TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/26/2024STOKStoke TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $13.003/26/2024STOKStoke TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00CARACara Therapeutics$20.97M1.69N/AN/A$1.05 per share0.62GTHXG1 Therapeutics$82.51M2.44N/AN/A$0.68 per share5.68NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ASTOKStoke Therapeutics$8.78M59.70N/AN/A$3.57 per share3.17Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/ACARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.95N/AN/AN/A-58.13%-106.04%-33.99%5/1/2024 (Confirmed)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)STOKStoke Therapeutics-$104.70M-$2.37N/AN/AN/AN/A-56.86%-41.59%5/2/2024 (Estimated)Latest CARA, STOK, ATNX, NXTC, and GTHX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/AGTHXG1 Therapeutics-$0.19N/A+$0.19N/AN/AN/A 3/25/2024Q4 2023STOKStoke Therapeutics-$0.62-$0.60+$0.02-$0.60$3.70 million$2.80 million3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/28/202412/31/2023GTHXG1 Therapeutics-$0.27-$0.21+$0.06-$0.21$12.83 million$14.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNXAthenexN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNXAthenex3.081.090.72CARACara TherapeuticsN/A4.544.43GTHXG1 Therapeutics1.463.873.45NXTCNextCureN/A16.3816.38STOKStoke TherapeuticsN/A6.996.99OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNXAthenex30.48%CARACara Therapeutics44.66%GTHXG1 Therapeutics24.21%NXTCNextCure42.65%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipATNXAthenex9.20%CARACara Therapeutics4.20%GTHXG1 Therapeutics8.23%NXTCNextCure11.90%STOKStoke Therapeutics12.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATNXAthenex6528.66 million7.87 millionOptionableCARACara Therapeutics5554.67 million52.36 millionOptionableGTHXG1 Therapeutics10052.23 million47.94 millionOptionableNXTCNextCure8227.90 million24.58 millionOptionableSTOKStoke Therapeutics11046.30 million40.61 millionOptionableCARA, STOK, ATNX, NXTC, and GTHX HeadlinesSourceHeadlineEarnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Declinezacks.com - April 25 at 11:07 AMStoke Therapeutics (NASDAQ:STOK) Trading 4.9% Higher marketbeat.com - April 24 at 3:36 PMStoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4%marketbeat.com - April 22 at 1:54 PMSkorpios Trust Sells 3,600,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stockamericanbankingnews.com - April 20 at 4:16 AMStoke-on-Trent to host its first comedy festivalyahoo.com - April 19 at 8:27 AMStoke City predicted starting XI vs Plymouth as Steven Schumacher weighs up old boys' claimsmsn.com - April 19 at 8:27 AMProtest outside Stoke-on-Trent Crown Court - here's whymsn.com - April 19 at 8:27 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stockinsidertrades.com - April 19 at 6:35 AMStoke Therapeutics (NASDAQ:STOK) Trading 4.5% Higher marketbeat.com - April 18 at 2:47 PMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerfinance.yahoo.com - April 17 at 8:40 AMStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officerbusinesswire.com - April 17 at 8:00 AMBridport 2-0 Stoke Gabriel & Torbay Police: Match reportbridportnews.co.uk - April 17 at 1:25 AMThe focus inside the Stoke City changing room ahead of Plymouth Argyle and 'biggest game of season'msn.com - April 17 at 1:25 AMHow killers planned Stoke DPD worker's 'public execution' before celebrating with blood-soaked weaponsstokesentinel.co.uk - April 17 at 1:25 AMStoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 12 at 9:48 AMQ2 2024 Earnings Forecast for Stoke Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:STOK)marketbeat.com - April 12 at 6:24 AMBuy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioningmarkets.businessinsider.com - April 12 at 12:09 AMStoke Therapeutics' (STOK) Buy Rating Reaffirmed at Needham & Company LLCmarketbeat.com - April 11 at 8:32 AMStoke Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.54) Per Share (NASDAQ:STOK)marketbeat.com - April 11 at 7:26 AMStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 6 at 2:43 AMStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferencebusinesswire.com - April 4 at 4:30 PMStoke Therapeutics (NASDAQ:STOK) Shares Up 5.1%marketbeat.com - April 4 at 2:24 PMAssessing Stoke Therapeutics: Insights From 6 Financial Analystsmarkets.businessinsider.com - April 4 at 2:16 PMStoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Cantor Fitzgeraldmarketbeat.com - April 4 at 10:16 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAthenexNASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Cara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.G1 TherapeuticsNASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Stoke TherapeuticsNASDAQ:STOKStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.